Prostate Cancer

Excited to see the latest @charlesrudin lab paper published in @ScienceTM: "Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers". #lungcancer #prostatecancer #SCLC #lineageplasticity https://t.co/sKHYNaave7 (@AlvaroQuintanal)

Unlocking #ProstateCancer treatment: The pathway of CAR T targeting prostate stem cell antigen. @TDorffOnc @cityofhope joins @CaPsurvivorship @DanaFarber to discuss promising options in managing advanced castration-resistant prostate cancer > https://t.co/fyZMrf16Uz (@urotoday)

Beyond BRCA-1 and 2: The impact of the #TALAPRO2 study on #ProstateCancer care. @cnsternberg @WCMEnglanderIPM joins @CaPsurvivorship @DanaFarber to discuss precision medicine's transformative impact on prostate cancer treatment. #WatchNow > https://t.co/1wCyan0v6L (@urotoday)

A recent study published in JNCI Cancer Spectrum demonstrates the real-world utility of @Veracyte's #Decipher Prostate Genomic Classifier in #ProstateCancer treatment. #ReadNow details on UroToday > https://t.co/NOVWZFh6wC @JNCI_Now @DrSpratticus @Davicioni (@urotoday)

PSMA-targeted radioligand therapy and #LiquidBiopsy characterizing #PSMA expression in men with metastatic castration-resistant #ProstateCancer. @AarmstrongDuke @DukeCancer joins @AndreaMiyahira @PCFnews to discuss the #PROPHECY trial on UroToday > https://t.co/tTiFnUVJOv (@urotoday)

🌟 PSCA-Targeted CAR T Cells Show Promising Anticancer Activity in Heavily Pretreated mCRPC 🌟 #ASCO23 @ASCO @ASCOPres @ASCOPost #prostate @tmprowell @PCFnews @APCCC_Lugano @EfstathiouEleni @Silke_Gillessen @OncoAlert #OncoAlertAF https://t.co/cyZtTlhS2J (@nataliagandur)

.@neerajaiims, of @huntsmancancer, speaks on the significance of the approval and how the combination of talazoparib and enzalutamide will fit into the treatment landscape of HRR gene–mutated mCRPC. #pcsm https://t.co/xbusmBgW8j (@OncLive)

Radio day! Join me today 6-8pE on @SIRIUSXM 110 @NYUDocs for a great program-@heatherhcheng & @CureBRCA on #BRCA in men, the @PCFnews prostate segment on surgery & radiation w Dr Shore, disparities in #prostatecancer w @hypertensionmd &drug induced erectile problems w @MariaUloko (@LoebStacy)

For patients with HRR gene–mutated mCRPC, additional data supporting the use of the combination of the PARP inhibitor talazoparib with enzalutamide is a welcome signal in the field. @neerajaiims @huntsmancancer #pcsm https://t.co/QMXZaAaaoU (@OncLive)

GU events are definitely a highlight of the @NRGonc meeting!! #NRG10 #NRG2023 Also huge congrats @tomboike for being named a 2023 @ASTRO_org Fellow (FASTRO)!! So exciting!! @MROQC1 represent 🙌👌 #pcsm #gusm #radonc (@jaguaranna27)

Discover the complexities of PSMA heterogeneity and regulation in metastatic #ProstateCancer with AR-positive and AR-negative phenotypes in this insightful discussion with @mishabeltran @DanaFarber and @AndreaMiyahira @PCFnews. #WatchNow on UroToday > https://t.co/pSgn6fDbJ3 (@urotoday)

It’s been wonderful catching up with my incredibly talented & hardworking mentors in #GU #GUSM #ProstateCancer at @NRGonc #NRG10 #NRG2023 including legends: 1️⃣ Dr. Daniel Spratt @DrSpratticus (@RadOncUH Chair via @UMichRadOnc, @MSKCancerCenter, & @VUMChealth:… https://t.co/5NetDokMzx (@jaguaranna27)

Primary analysis of #STARTAR: a phase 2 salvage trial for high-risk #ProstateCancer with biochemical recurrence. @TiansterZhang @utsw joins @CaPsurvivorship @DanaFarber to discuss treatment intensification in this conversation on UroToday > https://t.co/5NNRmuD48f (@urotoday)

Just in @trendscancer @CellPressNews 👉Recent advances in advanced #prostatecancer Rx: Lu-177, PARPi combos in mCRPC, doublets/triplets in mCSPC, and evolving targets👇 Weblink: https://t.co/L0cokxjZFd @ggebraelmd @GliceidaGalarza @umangtalking @OncoAlert @PCF_Science @urotoday (@neerajaiims)

Effective Treatment Options and Sequencing for Patients With Castration-Resistant #ProstateCancer Listen to Ep 2 of the @Medscape Prostate Cancer podcast series with host @sandysrimd and guest @shilpaonc. https://t.co/MLkFf7wjOc (@caseyannhickey)

Beautiful paper from @ggebraelmd, mentored by @neerajaiims @huntsmancancer, on the heels of his fantastic presentation at #KCRS23! Whether #kidneycancer or #prostatecancer, his command of the science and literature are amazing!!! @NeliMUlrich (@montypal)

Agarwal Discusses FDA Approval of Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC @neerajaiims @huntsmancancer @ASCO #ASCO23 #pcsm https://t.co/IIAaAi2fho (@OncLive)

Healio spoke with @LoebStacy regarding data showing that Black individuals are more likely to trust the accuracy of online video content about prostate cancer presented by Black physicians or patients compared with white presenters. @JAMANetworkOpen https://t.co/kX3g7ikp1E (@HemOncToday)

Hot off the press...@AACR @CRC_AACR publication showing metronomic admin of chemo inhibits epithelial to mesenchymal transition in aggressive #prostatecancer Amazing collaboration b/w @UABHeersink @AuburnU @TuskegeeUniv @harvardmed @HopkinsMedicine https://t.co/j6VxpGW5EE (@RaisBahrami)

CyberKnife® radiation therapy treats prostate cancer with targeted radiation while sparing healthy tissue in only 5 sessions. Watch Dr. Sean Collins (@SbrtSean) takes us behind the scenes of a CyberKnife treatment. For more information, visit https://t.co/XTZOajUWHl. (@MedStarGUH)

That’s a fantastic photo, Tony! This should be a poster for perseverance and for living life after a devastating metastatic prostate cancer diagnosis. You are an inspiration! (@TylerSbrt)

Exciting news!! @FrancisMedical announces first patient treated in #VAPOR2 pivotal study for water vapor ablation of #ProstateCancer. #ReadNow for details of this study on UroToday > https://t.co/PjInMCXOAi @arvinkgeorge @tanejauro @roboticurology (@urotoday)

Check out our review on Lutetium-177 PSMA for mCRPC. Excellent job by @PatellKanchi Excited to see all the great things you will accomplish in fellowship! @JasonBrownMDPhD @GUONCGarciaJA @DrSpratticus @angela_jia_ @CaseUHmed @cwruhemeonc @caseccc https://t.co/XGpyspiim1 (@MatthewKurianMD)

In this #ASCO23 interview, @SFreedlandMD of @CedarsSinai discusses his abstract on real-world characteristics and treatment by disease volume in metastatic castration-sensitive #prostate #cancer (#CSPC). Watch the conversation here! https://t.co/I8vY6qtUz7 #pcsm #ASCO (@OncData)

In this RCT, prostate cancer information was considered more trustworthy when delivered by a physician; racial concordance was associated with trust only among Black adults. https://t.co/vjPLz75q3G @LoebStacy @hypertensionmd @DrDMGriffith @HalaBorno @AishaLangford (@JAMANetworkOpen)

Hot off the press in @JAMANetworkOpen- our randomized trial of online #prostatecancer videos showing the importance of racial concordance & other factors associated w/ patient trust HT @hypertensionmd @HalaBorno @SamWashUro @DrDMGriffith @AishaLangford https://t.co/fK3GPKIFBI (@LoebStacy)

New #Medscape Podcast Series! In Ep 1 of the @Medscape Prostate Cancer podcast, host @sandysrimd sat down with @DrRanaMcKay to discuss androgen deprivation therapy and prostate cancer, including bone health, survivorship, and side effects #prostatecancer https://t.co/xGLGaWRhpD (@caseyannhickey)

New advances in the treatment of #mCRPC on @trendscancer by @neerajaiims @ggebraelmd @GliceidaGalarza @nsayeghmd @umangtalking #prostatecancer #ARPIs ➡️https://t.co/NnA0AYpZMj This is one of the #IUCS topics! Register now for free ➡️ https://t.co/0D3zEPXdWk (@urologysummit)

Part 2 of 2 How can radiopharmaceuticals be best used in the management of adult solid tumours? Join @drjasonstarr Prof. Jorge Garcia & @ErikMittraMD as they share their insights. Watch now: https://t.co/g2F4YA0zw7 #Endocrinology #Radiopharmaceuticals #ProstateCancer #GEPNETs (@touchENDOCRINE)

It has been a privilege to be part of such a great meeting! I hope I passed onto the student of this course the passion for cancer research on prostate cancer 💪🏻 @AndresC27622123 @G_Baciarello @matteolambe #myesmo #ProstateCancer (@PasRescigno)

Part 2 of 2 How can radiopharmaceuticals be best used in the management of adult solid tumours? Join @drjasonstarr Prof. Jorge Garcia and @ErikMittraMD as they share their insights. Watch now: https://t.co/1muW0TcjaM #Oncology #Radiopharmaceuticals #ProstateCancer #GEPNETs (@touchONCOLOGY)

Here's a super forward thinking study that I adore: PROTRACT - ctDNA TF informed treatment in advanced prostate cancer https://t.co/PxQ05kZsph Kudos to the study team from @VanProstateCtr Dr. Kim Chi @ResearchWyatt and BCCA! (@geoff_oxnard)

In the second article of the series, Alicia K. Morgans, MD, MPH, discussed results of the phase 3 PROpel trial of patients with #mCRPC. #pcsm | @CaPsurvivorship @DanaFarber https://t.co/RIOA0WGdGo (@TargetedOnc)

This week on The Podcast: @AdityaBagrodia and @ashleyrossmdphd discuss the role of genomics in active surveillance for #ProstateCancer. #MedEd #UroSoMe @NM_Urology @EdwardSchaeffer @HitenDPatel @amy_krambeck @cancerdrlane @JamesJmm23 @drphil_urology https://t.co/CQf3rROSKl (@_backtableUro)

This week on The Podcast: @AdityaBagrodia and @ashleyrossmdphd discuss the role of genomics in active surveillance for #ProstateCancer. @NM_Urology @EdwardSchaeffer @HitenDPatel @amy_krambeck @cancerdrlane @JamesJmm23 @drphil_urology @Decipher_VCYT https://t.co/CQf3rROSKl (@_backtableUro)

This week on The Podcast: @AdityaBagrodia and @ashleyrossmdphd discuss the role of genomics in active surveillance for #ProstateCancer. @NM_Urology @EdwardSchaeffer @HitenDPatel @amy_krambeck @cancerdrlane @JamesJmm23 @drphil_urology @Decipher_VCYT https://t.co/CQf3rROSKl (@_backtableUro)

Hey Prof, just FYI, some biomarker-driven prostate cancer clinical trials currently enrolling, thanks to @DrCraigGedye & @ANZUPtrials, including at @awrccentre and centres across Australia @RtnVic #pcsm #oncology (@CraigUnderhill)

🙅 Phase 3 NRG 0232 trial shows no benefit to adding EBRT to brachytherapy in localized #ProstateCancer ➡️ https://t.co/n3SUGYmlaT #PCSM #radonc @jmmrad (@JCO_ASCO)

Great Cases (CME) on #ProstateCancer with our @OncoAlert 🚨Colleague @neerajaiims 🇺🇸and many other GU experts brought to us by @mirrorsmed Click Link to Watch: https://t.co/EwCCLlwZoj (@weoncologists)

Dr. Scott Tagawa (@DrScottTagawa) from @WCMEnglanderIPM discusses the evolution of antibody-drug conjugates in metastatic castration-resistant #ProstateCancer, as well as potential future targets for ADC development with @OncLive. #mCRPC #ADCs #PMSA #PSCA https://t.co/qa0MJboZEl (@WCMEnglanderIPM)

Join us today at 1pm ET/6pm GMT+1 to discuss the top advances of the year in #GuCancer with @QMBCI researchers @tompowles1, @drfrankiejs, and Dr. Matthew Young. Read the article here: https://t.co/WWL08K4IVs @ChrisSweens1 #ACSCancerChat #blcsm #kcsm #pcsm #KCRS23 (@JournalCancer)

🚐The '#ManVan' is an innovative outreach programme that aims to boost early diagnosis of #ProstateCancer, led by the ICR's @Prof_Nick_James, @royalmarsdenNHS and @RMPartnersNHS, and funded by @NHSEngland. Check out the new testing unit at Stamford Bridge⬇️ (@ICR_London)